Financing provides capital to advance Freyya’s technology through the next regulatory milestones and toward building a foundation for commercialization.
It is with great sadness and a heavy heart that we inform you that our former Managing Director and company founder, Dr. Michael Rinck, passed away on September 10, 2026, at the age of 73. Dr. Michael Rinck founded our company in 1995 and, over many decades, shaped it with immense dedication, vision, and […]
bioMérieux Launches SPINCHIP® hs-cTnl, a Major Innovation for the Measurement of High-Sensitivity Cardiac Troponin I and Faster Management of Cardiac Emergencies
PDUFA target date set for March 16, 2027, following positive phase 3 results
National Institutes of Health Award Inherent Biosciences a Direct-to-Phase II SBIR Grant
Roundtable discussion, taking place in New York City, will examine the ongoing Ebola outbreak and technologies needed to strengthen future outbreak response.
Epitel’s REMI Neuro Monitoring System Selected for the FDA’s READI-Home Innovation Challenge
PARTICIPANT TESTS DIRECT NERVE INTERFACE OF THOUGHT-CONTROLLED “LUKE ARM” AT HOME
Thanks to all who joined us andt sponsored the event! Be sure to check out our event gallery!
Reinstein brings medtech and epilepsy experience as the company expands REMI® and enters its next stage of growth.
Study informed by encouraging exploratory efficacy findings and a favorable safety profile in the prior Phase 3 trial.
Investment led by Clene’s Chairman of the Board of Directors, alongside founding investor Kensington Capital Holdings, Clene’s CEO and other existing shareholders.
Blood-based testing could open new markets for the Co-Dx® PCR platform, including HIV and hepatitis B and C.
Vishal Sikri has been promoted to Executive Vice President – Commercial, effective September 16, 2026.
PDUFA Target Action Date Set for March 16, 2027.
Utah Medical Products acquires UK-based Orion Medical Supplies for $3.6 million to expand its Harm Reduction medical device distribution in Europe.
New cleaning and steam sterilization validation capabilities help manufacturers develop effective, repeatable, and regulatory-ready reprocessing instructions.
BioUtah joined Utah State University on September 4 for the 2026 USU/BioUtah Networking Lunch at the David B. Haight Alumni Center in Logan, with about 55 guests registered. The event brought together Utah life sciences industry members and USU faculty and staff for networking, lunch, and a set of short presentations connecting the industry with […]
Halia Therapeutics to Present at the Morgan Stanley 24th Annual Global Healthcare Conference
Collaboration brings together complementary expertise and proprietary technologies to advance a next-generation radiopharmaceutical candidate with the potential to enhance tumor targeting.
Two full laboratory installations completed in Florida; installation and customer training underway in Indiana.
Localized cloud environment is designed to support ongoing clinical studies and establish the digital foundation for future data commercialization strategies
Agreement covers the establishment of a national programme to enable U.S. healthcare providers the ability to access and order the Renalytix kidneyintelX.dkd test.
Several life sciences companies honored at 2026 Utah Business Innovation Awards.
BXCL501, a novel dexmedetomidine sublingual film, is under FDA review for potential at-home (outpatient) use for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.
Shipments of laboratory equipment and other mosquito abatement materials to overseas USAF base represent first international expansion of Vector Smart product line.
U.S. Representative Celeste Maloy (R-UT) on Aug. 19 toured the Biologic Input Output Systems (BIOS) lab, part of the University of Utah’s Craig H. Neilsen Rehabilitation Hospital, to observe research into prosthetics innovation. Led by University of Utah NeuroRobotics Lab Director and BIOS Chief Scientist Jacob “Jake” George, alongside BIOS Chief Development Officer Tim Miller, […]
Ecopipam (EBS-101) is a first-in-class selective D1 (dopamine) receptor antagonist with Orphan Drug designation
SALT LAKE CITY, Aug. 19, 2026 /PRNewswire/ — Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, announced today that Scott Gleason has been appointed Chief Financial Officer (CFO), effective August 31, 2026. Mr. Gleason brings more than 25 […]
Sheri Lewis has agreed to join Merit as Executive VP of Global Operations, effective August 31.
Utah lawmakers on Aug, 19 attended a breakfast meeting of the Utah Life Sciences Innovation Caucus (ULSIC).
Combined operations deliver unified trial delivery, faster recruitment, and expanded evidence-generation capabilities.
